Pharmaceutical Technology

JUNE 4, 2023

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence.

Gene Therapy 246

Gene Therapy DNA Gene Genetics 246

Pharmaceutical Technology

JULY 1, 2022

Blueprint Medicines has entered strategic financing partnerships for up to $1.25bn with life sciences-focused investors Sixth Street and Royalty Pharma. The company noted that the deal will bring substantial non-dilutive, low-cost capital to boost innovation and growth. The collaboration with Sixth Street has three parts.

Medicine 147

Medicine Business Development Sales Life Science 147

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Jörg Schüttrumpf Chief Scientific Innovation Officer Grifols Grifols, with its roots tracing back to the early 20th century, has been instrumental in shaping this sector.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Drug Discovery World

OCTOBER 5, 2023

Join DDW’s Megan Thomas and Reece Armstrong with sponsors Taconic for the first DDW Turning Science into Business Summit, ‘ Cancer research opportunities and advances ’, on 16 November at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. More to be announced.

Research 52

Research Antibody Medicine RNA 52

pharmaphorum

JANUARY 17, 2023

Late last year, pharmaphorum spoke with AstraZeneca’s Ben Challis, VP and head of translational science and experimental medicine, cardiovascular, renal, and metabolism (CVRM), together with Magnus Jörnten-Karlsson, executive director of Unify. Dissecting heterogeneity. Digital technology and ‘frictionless’ clinical trials.

Clinical Trials 98

Clinical Trials Clinical Trials Medicine Trials 98

Drug Discovery World

OCTOBER 26, 2023

Taking place on 5 and 6 February 2024, the Ignite Theater will be open to all attendees and will explore how drug discovery technology is driving innovation from bench to bedside.

Drugs 52

Drugs Medicine Development Research 52

Drug Discovery World

AUGUST 24, 2023

The White House Cancer Moonshot initiative has announced a new public-private partnership to boost innovation in the fight against cancer. CancerX will be co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center. SimBioSys will be one of the founding members of the CancerX initiative. “As

Medicine 52

Medicine Drugs Research Development 52

Cloudbyz

MARCH 6, 2024

This allows for the creation of highly specific and targeted therapies that can modulate biological pathways with remarkable precision. Personalized Medicine: Biologics offer the potential for personalized treatment approaches by taking into account individual variations in genetics, immune responses, and disease characteristics.

Gene 73

Gene Immune Response Manufacturing Gene Therapy 73

pharmaphorum

FEBRUARY 11, 2021

In the second episode of our Health Innovators series, Paul Tunnah speaks to longevity investor Sergey Young about breakthrough technologies that may overcome the negative effects of ageing. The Science and Technology of Growing Young” – pre-order amzn.to/36WGIVC. How can humans extend their life span?

Medicine 52

Medicine Development Drugs 52

Drug Discovery World

DECEMBER 27, 2023

DDW Highlights Innovative. In Conversation With In the In Conversation With series, Thomas speaks with members of the drug discovery industry about their work and how it helps turn science into business. Dr Pace discusses how precision medicine is already starting to influence standards in clinical trial design.

Clinical Trials 69

Clinical Trials Clinical Trials Drugs Development 69

Drug Discovery World

JULY 20, 2022

Precision medicine start-up Vesynta has become the first medtech company to move into a laboratory at south London’s latest incubator space. . Adaptive and Responsive Nanomaterials group at University College London, has moved into the Innovation Gateway at The London Cancer Hub in Sutton. Official comments .

Life Science 52

Life Science Medicine Research Development 52

Pharmaceutical Technology

MAY 8, 2023

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence.

Genetics 130

Genetics DNA Genetic Engineering Antibody 130

Drug Discovery World

OCTOBER 12, 2023

Hosted by DDW and sponsored by ACRO Biosystems, ‘Innovative advances in neuroscience’ will be free to attend on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. Join this free webinar to learn about innovation taking place in the neuroscience field. Register free here.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

FEBRUARY 5, 2024

The launches include an integrated solution suite for liquid biopsy workflows, and the Resolvex i300 and antibody purification columns AffinEx Protein A Capture, adding biomarker discovery, drug development and personalised medicine research to proteomics workflows.

Gene Therapy 64

Gene Therapy Life Science Production Dermatology 64

Drug Discovery World

SEPTEMBER 26, 2023

Although not a new area of science, the prominence of this technology and its applications – evident during the Covid-19 pandemic – have increased of late. This has created advances in the development of new medicines and our ability to find solutions for unmet medical needs.

Drugs 52

Drugs Marketing Gene Development 52

Drug Discovery Today

JULY 14, 2020

Manchester’s world-class health innovation and precision medicine campus - a joint venture between Manchester University NHS Foundation Trust (MFT), the UK's largest NHS provider Trust, and Manchester Science Partnerships (MSP), took a step forward today as Citylabs 2.0 reached practical completion.

Medicine 40

Medicine 40

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 102

Genome Genomics Medicine Development 102

Drug Discovery World

NOVEMBER 2, 2023

It’s less than one week now till our exclusive online event ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation. Secure your place!

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

OCTOBER 26, 2023

Register now to hear from neuroscience industry experts at ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation. Secure your place!

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

FEBRUARY 20, 2024

The new report says the anticipated growth to 2028 will be fuelled by the expansion of precision medicine, advancements in drug-drug interaction prediction, analysis of patient-derived data, development of biosimilars, and the increasing number of drug candidates.

Marketing 52

Marketing Drugs Life Science Genome 52

Drug Discovery World

MARCH 13, 2024

With government support and strong academic institutions, does Singapore have what it takes to become a global centre for life sciences? DDW’s Diana Spencer explores how the country is turning pioneering science into a successful biotech industry. UK-based molecular diagnostics group Yourgene operates in Singapore.

Life Science 69

Life Science Genome Genomics Research 69

The Pharma Data

MAY 26, 2023

“At ASCO, Pfizer will present new data across the four key areas of our industry-leading portfolio – breast cancer, genitourinary cancer, hematology, and precision medicine – and for the first time, first-in-human data for some of our most exciting pipeline medicines,” said Chris Boshoff, M.D.,

Medicine 52

Medicine Clinical Development Antibody Development 52

The Pharma Data

OCTOBER 19, 2020

Caris’ collaborative network focused on expanding the application of precision medicine in oncology supports Winship’s enterprising approach to research leading to transformative discoveries in cancer care and treatment. MBA, FACP, Chairman of the Caris Precision Oncology Alliance. IRVING, Texas and ATLANTA , Oct.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

The Pharma Data

OCTOBER 9, 2021

Collaboration Leveraging Neumora’s Precision Neuroscience Platform with Amgen’s deCODE Human Genetics Capabilities to Advance Innovative Medicines for Brain Disease. Reese, M.D., executive vice president of Research and Development at Amgen. Berns, co-founder, chairman and chief executive officer at Neumora.

Genetics 40

Genetics Medicine Development Genome 40

Drug Discovery World

DECEMBER 14, 2023

In early December 2023, the University of Glasgow announced plans to construct a new Health Innovation Hub in Govan in Glasgow. A centre of excellence for cancer research The announcement of the new Health Innovation Hub follows other examples of significant investment in Glasgow life sciences.

Drugs 75

Drugs Life Science Research Scientist 75

Drug Discovery World

OCTOBER 19, 2023

Hosted by DDW and co-sponsored by ACRO Biosystems, ‘Innovative advances in neuroscience’ will be free to attend on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

OCTOBER 26, 2023

Register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading figures. The free two-hour summit will outline areas of opportunity in the oncology market and will feature insights from thought leaders in cancer research, precision medicine and immunotherapy.

Research 52

Research Antibody Vaccination Vaccine 52

Drug Discovery World

JANUARY 2, 2024

Cancer Research Horizon’s Innovation Summit 2023 took place on 21 November 2023 at the Royal Society of Medicine, and included talks from researchers translating their research, as well as networking with members of the entrepreneurial ecosystem. DDW’s Megan Thomas spoke to a range of attendees. She said: “The speed is not sustainable.

Research 59

Research Vaccination Vaccine Medicine 59

The Pharma Data

JUNE 14, 2023

This specific method of action that Cedilla has discovered allows for precise targeting in a selected patient population with high unmet need and has the potential to enhance safety and efficacy in comparison to standard of care. Cedilla will also be eligible to receive royalties on medicines based on their technology commercialized by Bayer.

Licensing 40

Licensing Licensing Life Science Development 40

Drug Discovery World

OCTOBER 20, 2022

They are called “ The potential of small molecules and biologics for new therapeutics ”, “ AE reporting turnarounds and the translation issue ” and “ Why we are on the cusp of a golden age of medicine ”. In the second article, Kathleen O’Brien of Amplexor Life Sciences lays out a blueprint for centralising global AE reporting.

Development 52

Development Drugs Life Science Genome 52

pharmaphorum

NOVEMBER 16, 2021

In the second of a two-part series, Leela Barham argues that whilst international comparisons of uptake are useful, there could be more to gain from looking at more medicines and their uptake in England rather than looking at a small set of medicines and their uptake internationally. Consistently focus on innovative medicines.

Medicine 90

Medicine Branding Gene Therapy Life Science 90

pharmaphorum

OCTOBER 4, 2022

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and investments – projected to be enough for funding into 2025. This is due to close concurrently with the merger.

Gene Therapy 112

Gene Therapy Gene Life Science Genetics 112

pharmaphorum

MARCH 29, 2021

The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the future of drug development in the UK? Part of this is about making sure the processes we use to evaluate new medicines are fit for purpose. Evolving landscape.

Medicine 86

Medicine Life Science Drugs Development 86

Drug Discovery World

MARCH 7, 2023

DDW Editor Reece Armstrong takes a look at Qatar’s drug discovery and life sciences market, exploring how the country is utilising innovative technologies in its approach to healthcare. The Middle East represents one of the world’s most lucrative markets for pharmaceuticals.

Biobanking 52

Biobanking Drugs Genome Genomics 52

The Pharma Data

MARCH 1, 2022

to build a scalable data, analytics, and infrastructure platform This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine. Boehringer Ingelheim partners with Lifebit Biotech, Ltd.

Biobanking 52

Biobanking Genome Genomics Genome Project 52

pharmaphorum

SEPTEMBER 16, 2022

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. Human-first precision health. Kim recognised then, he said, that better tools for medicine needed to be developed, and that they still do.

Development 134

Development Research Drugs Clinical Trials 134

Drug Discovery World

OCTOBER 20, 2022

They are called “ The potential of small molecules and biologics for new therapeutics ”, “ AE reporting turnarounds and the translation issue ” and “ Why we are on the cusp of a golden age of medicine ”. In the second article, Kathleen O’Brien of Amplexor Life Sciences lays out a blueprint for centralising global AE reporting.

Development 52

Development Drugs Life Science Genome 52